Mass vaccination with Pfizer's COVID vaccine lowers death rates, hospitalisations and disease
Experimental study: At least one thing in the experiment was changed to see if it had an impact on the subjects (often people or animals) – eg: changing the amount of time mice spend on an exercise wheel to find out what impact it has on weight loss.
Observational study: A study in which the subject is observed to see if there is a relationship between two or more things (eg: the consumption of diet drinks and obesity). Observational studies cannot prove that one thing causes another, only that they are linked.
Case study: A study involving observations of a single patient or group of patients.
People: This is a study based on research using people.
A nationwide mass-vaccination using the Pfizer vaccine is effective for a wide range of COVID outcomes, according to international researchers who looked at almost 600,000 people vaccinated between December 20, 2020 and February 1, 2021 and compared them to unvaccinated people of similar demographics. After the second vaccine dose, they estimate that the vaccines were around 92 per cent effective at reducing infection, 87 per cent effective in reducing hospitalisation, and 92 per cent effective in reducing severe disease. For days 14 to 20 after the first dose, deaths from COVID were also estimated to have been reduced by 72 per cent.
Journal/conference: NEJM
Link to research (DOI): 10.1056/NEJMoa2101765
Organisation/s: Ben Gurion University of the Negev, Israel
Attachments:
Note: Not all attachments are visible to the general public
